Everyday foundations · Evidence Explainer

LIFTMOR improved bone density in a small supervised trial—not fracture prevention

The useful description is small, screened and supervised. Eight months of closely coached high-intensity resistance and impact training improved BMD and several functional measures versus home low-intensity exercise, but the trial did not establish fewer fragility fractures or general unsupervised safety.

Reviewed under standing publication authorization

Discovery, counterevidence, claim mapping, identifiers, funding, correction state and prose were reviewed before release.

Evidence box

Promising BMD and function findings under close supervision

Study type
Small randomized active-control exercise trial with vertebral-morphology follow-up
Studied in
Screened postmenopausal women with low bone mass; mean age 65
Participants / sample
101 randomized; 43 per group in the reported per-protocol analysis
Publication status
Peer-reviewed primary and safety reports; retrospectively registered; published erratum retained
Outcome type
Bone-mineral density, strength, function, adherence, adverse events and vertebral morphology
Development stage
Completed research exercise protocol; not a standardized unsupervised program
Conflicts / funding
Griffith University and The Bone Clinic affiliations; later commercial translation disclosed
Our assessment
Promising supervised BMD and function results—not fracture prevention, universal safety or longevity evidence
Reporting confidence
High for bounded trial results; low for unsupervised, fracture or longevity generalization

Start here

Key takeaways

  • Per-protocol lumbar-spine BMD changed +2.9% with HiRIT versus −1.2% with low-intensity exercise.
  • Femoral-neck BMD changed +0.3% versus −1.9%, and several measured strength/function outcomes favored HiRIT.
  • The trial was too small and short to establish fewer fragility fractures, mortality benefit, healthspan or lifespan extension.

Supervision is part of the intervention

Do not detach the result from screening and coaching.

What was studied

  • Twice-weekly, 30-minute sessions progressed above 85% one-repetition maximum with impact loading.
  • Participants were screened and closely supervised for eight months.

What was not established

  • Safety or effectiveness of unsupervised high-intensity lifting in an unselected population.
  • Reduction in fragility fractures, disability, mortality, healthspan or lifespan.

Evidence at a glance

BMD, function, safety and fracture are separate lanes.

Rows preserve what was measured; they are not a program score or exercise prescription.

Selected LIFTMOR outcomes
OutcomeResultBoundary
Lumbar-spine BMD+2.9% versus −1.2%.Per-protocol biomarker outcome.
Femoral-neck BMD+0.3% versus −1.9%.Not a fracture endpoint.
Strength and functionSeveral measured outcomes favored HiRIT.Specific tests in a small selected sample.
Safety and fractureOne minor back spasm; no incident vertebral deterioration in the assessed sample.Insufficient for unsupervised safety or fracture prevention.
01

The bottom line

LIFTMOR randomized 101 screened postmenopausal women with low bone mass to supervised high-intensity resistance and impact training or home-based low-intensity exercise. Per-protocol BMD and several function measures favored the supervised program. The trial did not establish fewer fragility fractures.

02

Why this matters

People with low bone mass are often warned away from heavy lifting, while promotional summaries can swing too far and imply that heavy training is universally safe. LIFTMOR is more specific: it tested a carefully progressed, coached protocol in selected volunteers.

03

What researchers did

The HiRIT group trained twice weekly for 30 minutes, progressing above 85% of one-repetition maximum and adding impact loading. The comparator performed home-based low-intensity exercise. The active comparison and close supervision are part of the result, not incidental details.

04

What they found

Among 43 per-protocol participants in each group, lumbar-spine BMD changed +2.9% versus −1.2% and femoral-neck BMD +0.3% versus −1.9%. Compliance was about 92% in HiRIT. Several strength and function measures also favored the program.

05

How strong is the evidence?

Randomization supports the measured group comparison, but the small sample, per-protocol emphasis, short duration, retrospective registry and selected volunteers limit certainty and generalization. BMD is useful but cannot substitute for a fracture endpoint.

06

What this evidence does not show

LIFTMOR did not establish fewer fragility fractures, lower mortality, longer healthspan or lifespan. One minor back spasm and no observed vertebral deterioration in a small assessed sample do not establish safety for unscreened or unsupervised training.

07

Safety, interpretation, and funding

The protocol involved screening, technique instruction and close supervision. Author affiliations included Griffith University and The Bone Clinic, and later commercial translation requires visible context. Clinic marketing is not independent efficacy evidence.

08

What happens next

Larger and longer trials can test fragility fractures, adverse events, adherence and transfer to broader populations. Comparisons should preserve the level of supervision and distinguish a reproducible protocol from the general idea of lifting heavily.

Primary sources

Sources, roles and limits

  1. LIFTMOR randomized trial
    Identifier
    PMID:28975661 · DOI:10.1002/jbmr.3284 · ACTRN12616000475448
    Role
    Primary randomized support
    Limitation
    Small, selected, supervised sample with per-protocol outcome emphasis.
  2. Vertebral-morphology and safety analysis
    Identifier
    PMID:30612163 · DOI:10.1007/s00198-018-04829-z
    Role
    Bounded safety and morphology context
    Limitation
    Not powered to establish fracture prevention or unsupervised safety.
  3. Published LIFTMOR erratum
    Identifier
    PMID:30861219 · DOI:10.1002/jbmr.3659
    Role
    Correction notice
    Limitation
    Corrects named table details; does not create a new efficacy outcome.
  4. ANZCTR record
    Identifier
    ACTRN12616000475448
    Role
    Registry identity
    Limitation
    Retrospective registration is a maturity limitation and not validation.

Connected topics

Continue through the knowledge system

Intervention categoriesStudy and trial recordsHow evidence differsEveryday foundation stories

Continue with real coverage

Keep reading

These are learning paths, not rankings, recommendations, or evidence that the stories support one another.

Disclosures and history

  • August 2, 2026 — source discovery, verification and counterevidence completed before prose drafting.
  • August 2, 2026 — atomic claim map, supervision boundary, funding and prose reviewed.
  • March 11, 2019 — published erratum corrected table headings and the calcium-intake-change sign without reversing a bone or fracture outcome.